On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?

Gaurav Varma; Catherine S Diefenbach

doi:10.1158/1078-0432.CCR-23-1571

On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?

Clin Cancer Res. 2023 Oct 13;29(20):4024-4026. doi: 10.1158/1078-0432.CCR-23-1571.

Authors

Gaurav Varma^{1

2}, Catherine S Diefenbach^{1

2}

Affiliations

¹ Division of Hematology and Medical Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, New York.
² Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York.

PMID: 37581573
DOI: 10.1158/1078-0432.CCR-23-1571

Abstract

To date, mAbs have had limited success in improving outcomes for patients with T-cell lymphomas. Preclinical data suggest that anti-T-cell receptor Vβ-segment mAbs are a novel therapeutic strategy for patients with T-cell lymphomas that avoid several limitations of current therapies. See related article by Lucero et al., p. 4230.

Publication types

Editorial
Comment